---
id: 208
title: Intra-Abdominal Infections (IAI)
category: clinical_syndromes
subcategory: gastrointestinal
tags: [IAI, peritonitis, secondary-peritonitis, source-control, pip-tazo, carbapenem]
difficulty: high
---

## Question

How are intra-abdominal infections managed? Use **"Source Control + Pip-Tazo/Carbapenem × 4-7d, Extend if No Source Control"** framework.

## Answer

### **Classification:**

**Community-Acquired (CA-IAI):**
- **Acute onset** (<7 days)
- **No healthcare exposure** (within 90 days)
- **Common sources:** Appendicitis, diverticulitis, cholecystitis, perforated viscus

**Healthcare-Associated (HA-IAI):**
- **Hospital onset** (≥48h admission)
- **Recent surgery, procedures**
- **Risk for MDROs** (ESBL, *Pseudomonas*, *Enterococcus*, *Candida*)

### **Severity Classification:**

**Mild-Moderate (Uncomplicated):**
- **Localized process** (contained abscess, early perforation)
- **No organ dysfunction**
- **Can be managed with source control + antibiotics**

**Severe (Complicated):**
- **Diffuse peritonitis**
- **Septic shock, organ dysfunction** (SOFA ≥2)
- **Failed source control**

### **Microbiology:**

**Common Pathogens (Polymicrobial):**
- **Gram-negatives:** *E. coli* (most common), *Klebsiella*, *Enterobacter*, *Proteus*
- **Anaerobes:** *Bacteroides fragilis* (most important), *Clostridium*, *Prevotella*
- **Gram-positives:** *Enterococcus* (especially healthcare-associated)
- **Fungi:** *Candida albicans* (if recurrent surgery, upper GI perforation, healthcare-associated)

**Risk Factors for MDROs:**
- **Healthcare-associated** IAI
- **Recent antibiotics** (within 90 days)
- **Immunosuppression**
- **Inadequate source control**

### **Empiric Treatment:**

**Community-Acquired, Mild-Moderate:**

**Preferred:**
- **Piperacillin-tazobactam 3.375-4.5g IV q6-8h**
- **Ceftriaxone 1-2g IV daily + metronidazole 500mg IV q8h**
- **Ertapenem 1g IV daily** (outpatient-capable if stable)

**Alternative:**
- **Ciprofloxacin 400mg IV q12h + metronidazole 500mg IV q8h**
- **Cefazolin 1-2g IV q8h + metronidazole** (if low risk for ESBL)

**Community-Acquired, Severe OR Healthcare-Associated:**

**Preferred:**
- **Meropenem 1g IV q8h** OR **imipenem 500mg IV q6h**
- **Piperacillin-tazobactam 4.5g IV q6h** (extended infusion)

**If MRSA Risk:**
- **Add vancomycin 15-20 mg/kg IV q8-12h**

**If *Candida* Risk (Upper GI Perforation, Recurrent Surgery):**
- **Add echinocandin** (micafungin 100mg IV daily, caspofungin 70mg × 1 → 50mg daily, anidulafungin 200mg × 1 → 100mg daily)
- OR **fluconazole 400mg IV daily** (if azole-susceptible, hemodynamically stable)

### **Duration:**

**Adequate Source Control + Clinical Improvement:**
- **4 days** (if source controlled, patient improving)
- **Extend to 7 days** if:
  - Delayed source control (>24h)
  - High-risk pathogens (*Candida*, *Enterococcus*)
  - Clinical non-improvement

**Inadequate Source Control:**
- **Continue antibiotics** until definitive control achieved
- **Do NOT use prolonged antibiotics as substitute** for source control

### **Source Control:**

**Principles:**
- **Remove infected material** (drain abscess, resect necrotic tissue)
- **Control contamination** (repair perforation, divert fecal stream)
- **Restore anatomy/function**

**Methods:**
- **Percutaneous drainage** (CT-guided, for localized abscess >3-5 cm)
- **Surgical drainage/debridement** (laparotomy, laparoscopy)
- **Timing:** **Within 24 hours** (mortality increases with delay)

### **Special Situations:**

**Secondary Peritonitis:**
- **Perforation of hollow viscus** (most common)
- **Requires source control + antibiotics**

**Tertiary Peritonitis:**
- **Persistent/recurrent infection** (>48h after adequate source control)
- **Often low virulence organisms** (CoNS, *Enterococcus*, *Candida*)
- **Poor prognosis** (50% mortality)
- **Re-assess source control** (leak, abscess, foreign body)

**Spontaneous Bacterial Peritonitis (SBP):**
- **See separate card** (different pathophysiology, treatment)

**Post-Operative IAI:**
- **High risk for MDROs** (*Enterococcus*, *Candida*, ESBL, *Pseudomonas*)
- **Broad-spectrum empiric coverage** (meropenem + vancomycin ± echinocandin)

### **De-escalation:**

**Narrow Based on Cultures:**
- **Switch to narrower agent** once susceptibilities available
- **Stop anti-MRSA, anti-fungal** if not isolated
- **Reassess need for continuation** at day 4

### **Prognosis:**

**Mortality:**
- **CA-IAI (mild):** <5%
- **CA-IAI (severe):** 10-30%
- **HA-IAI:** 20-50%

**Risk Factors for Poor Outcome:**
- **Delayed source control** (>24h)
- **Inadequate source control**
- **Severe sepsis/shock**
- **Age >65, comorbidities**

## Key Points

### **Source Control is Critical:**
- **Within 24 hours** (every hour delay ↑mortality)
- **Antibiotics NOT substitute** for drainage/repair

### **Empiric = Pip-Tazo or Carbapenem:**
- **CA-IAI (mild):** Pip-tazo OR ceftriaxone + metronidazole
- **Severe/HA-IAI:** Meropenem OR pip-tazo (high dose)

### **4-7 Days Duration:**
- **4 days adequate** if source controlled + improving
- **7 days** if delayed control, high-risk pathogen

### **Add Antifungal if Upper GI, Recurrent Surgery:**
- **Echinocandin** (micafungin, caspofungin, anidulafungin)
- OR **fluconazole** (if stable, azole-susceptible)

### **De-escalate Based on Cultures:**
- **Stop MRSA, fungal coverage** if not isolated
- **Narrow to susceptible agent**

### **Clinical Pearls:**
- **Source control <24h + pip-tazo × 4 days** (if adequate control + improving)
- **Extend to 7 days** if delayed control, high-risk pathogen
- **Add echinocandin** if upper GI perforation, recurrent surgery, healthcare-associated
- **Polymicrobial:** *E. coli* + *Bacteroides fragilis* most common
- **Tertiary peritonitis:** Persistent infection despite control (*Enterococcus*, *Candida*, CoNS)

## Sources

- [IDSA/SIS: Intra-Abdominal Infection Guidelines 2024]
- [JAMA Surgery: Source Control in IAI 2024]

## Media

N/A
